(Q34644401)

3 August 2017

1 reference

title

Luteinising hormone-releasing hormone antagonists in prostate cancer therapy (English)

1 reference

3 August 2017

1 reference

Pavlos Msaouel

1

1 reference

3 August 2017

Evanthia Diamanti

series ordinal

2

1 reference

3 August 2017

Marinela Tzanela

series ordinal

3

1 reference

3 August 2017

Michael Koutsilieris

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Emerging Drugs

3 August 2017

1 reference

3 August 2017

12

1 reference

3 August 2017

2

1 reference

3 August 2017

285-299

1 reference

Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Integrative molecular concept modeling of prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Endocrine approaches in the therapy of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Clinical features of metastatic bone disease and risk of skeletal morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

National Comprehensive Cancer Network guidelines for the management of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

The Akt pathway: molecular targets for anti-cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Endocrine therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Development of prostate cancer treatment: the good news

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Endocrine treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Different effects of agonistic vs. antagonistic gnrh-analogues (triptorelin vs. cetrorelix) on bone modeling and remodeling in peripubertal female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

GnRH analogues--agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Non-peptidic GnRH receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Return to fertility after extended chemical castration with a GnRH antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Current advances in sustained-release systems for parenteral drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

21 January 2018

GnRHs and GnRH receptors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

GnRH-antagonists in reproductive medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.285

10.1517/14728214.12.2.285

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference